Gyre Therapeutics, Inc. (GYRE) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $7.34: Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.12% of cap); Below 200-MA, MA slope -3.2%/30d (confirmed downtrend).
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment... Read more
Sell if holding. Multiple concerning factors at $7.34: Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.12% of cap); Below 200-MA, MA slope -3.2%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 74. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $7.34: Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.12% of cap); Below 200-MA, MA slope -3.2%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $6.83. Score 5.3/10, moderate confidence.
Take-profit target: $15.87 (+116.2% upside). Prior stop was $6.83. Stop-loss: $6.83.
Below 200-MA, MA slope -3.2%/30d (confirmed downtrend); Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.12% of cap).
Gyre Therapeutics, Inc. trades at a P/E of N/A (forward 122.3). TrendMatrix value score: 6.0/10. Verdict: Sell.
9 analysts cover GYRE with a consensus score of 4.2/5. Average price target: $19.
What does Gyre Therapeutics, Inc. do?Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule,...
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.